PAINWeek report flags kratom screening limits in emergency care

Why it matters

Emergency clinicians may not detect kratom on standard urine immunoassays, and presentations can involve complex drug interactions. The report highlights diagnostic challenges rather than establishing new treatment guidance.

The big picture

Psychiatry Advisor summarizes three kratom-related posters presented at PAINWeek in Las Vegas in September 2026. The underlying hospital, poison-control, and literature data cited in the report end between 2019 and 2024, so they do not measure current product or exposure patterns.

Key findings

• A retrospective analysis of national emergency department data cited in the report found a significant rise in kratom-related encounters from 2016 to 2019, with estimated annual visits above 10,000 by the end of that period.
• The article says poison-control reports rose from 1,807 in 2017 to more than 2,400 in 2020; it cites 7% to 9% of reports as involving major effects or death.
• Poster authors described routine urine immunoassays as generally unable to detect kratom metabolites, which can complicate emergency assessment.
• The report draws on conference posters and datasets ending by 2024, rather than a new 2026 patient study.

What they say

The researchers described kratom-related presentations as "a growing and clinically heterogeneous challenge for emergency medicine," according to the report.

Bottom line

The report urges clinicians to consider kratom in toxicology evaluations, while its cited data predate 2025.